Anas Younes, M.D. @DrAnasYounes Twitter profile

Last Seen Profiles

@BinorRaja

@StNiniansPE

@sydmolga

@poyoaxie

@LaingNikolaus

@b6MZ4TuG0944al

@bodydiscret69

@magmai_sub

@shimakotohdoh

@redbecomesyou

@djstandaman

@GoddessCoco6

@marialealopeira

@christanova

@NatGeoPhotos

@AlexaTabonmay

@SuiElonPePe

@CTaylor3112

@Tsutayadazaifu

@Imbqun

@GehlPetron

@JongSocContract

@ran_emoechi

@Official_NODO

@GerrySchwe37033

@MarbRwbh23356

@RoukHein

@game_love2zigen

@hi_sp_Bowling

@jdh144417856528

@wxrdna

@BCUWeArePR

@TheMajorityV

@lindaosull88

@ayane1768612

@SoupxLisa

Anas Younes, M.D.

@DrAnasYounes

5 years

In Clinic: Nothing is more gratifying than helping patients achieve a remission and go back to their normal lives (PET scan image of an 81 year man with diffuse large B cell lymphoma before (left) and after 2 cycles of therapy)

14

76

395

Anas Younes, M.D.

@DrAnasYounes

2 years

Thrilled to announce that Dr Nina Shah ( @ninashah33 ) will be joining our hematology R&D team as the Global Head of Multiple Myeloma Clinical Development and Strategy. Nina is an international expert in multiple myeloma clinical care and clinical investi…

59

24

339

Anas Younes, M.D.

@DrAnasYounes

4 years

Jose left this world too soon. R.I.P. my friend

13

11

211

Anas Younes, M.D.

@DrAnasYounes

6 years

Nothing more rewarding than having your patient cured and come back with a new baby.

3

7

165

Anas Younes, M.D.

@DrAnasYounes

4 years

Good to be back in the office after a long lockdown..or to be more accurate, good to be in the new office for the first time...Looking forward to working with colleagues across the globe to develop better treatments to improve the cure for patients with blood cancers

16

4

146

Anas Younes, M.D.

@DrAnasYounes

4 years

Beautiful tributes and celebrations of jose baselga’s life by his friends and colleagues

6

7

123

Anas Younes, M.D.

@DrAnasYounes

2 years

Thrilled to announce that Dr. Jude Fitzgibbon will be joining our hematology R&D team as the Vice President, Head of Discovery and Target Biology. Welcome to the Heme R&D team, Jude!

16

5

123

Anas Younes, M.D.

@DrAnasYounes

6 years

Highlight of my day: had a coffee with a previous patient of mine. In remission for 8 years after experimental therapy. Now married with 2 beautiful kids. #ASC018

5

15

118

Anas Younes, M.D.

@DrAnasYounes

4 years

Just finished clinic. Telemedicine is good for certain patients with routine follow up visits, but not ideal for evaluating new symptoms, or for communicating new findings or disease progression on imaging studies.

9

13

110

Anas Younes, M.D.

@DrAnasYounes

4 years

I guess it is official now! Thanks to all who participated in these video messages.. Means a lot to me...

Tribute for Anas Younes - Workplace Tribute for Anas Younes

We're creating a video montage (or "Tribute") for Anas Younes and want you to join us. It will only take you a minute to record your video and you can do it from any device. Click on the link to...

www.tribute.co

39

7

109

Anas Younes, M.D.

@DrAnasYounes

3 years

Another drug developer and a thought leader rock star joins our hematology R&D team. We are on a mission to change treatment outcome for patients with blood cancers. Welcome to the team Simon ⁦ @rule_simon ⁩

7

6

104

Anas Younes, M.D.

@DrAnasYounes

4 years

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups | Blood Cancer Journal

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-r...

Blood Cancer Journal - Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

www.nature.com

1

29

95

Anas Younes, M.D.

@DrAnasYounes

3 years

Sad to hear about the passing of prof Ton Hagenbeek of the Academic Medical Center, Univ of Amsterdam. Ton was a world class expert on lymphoma and made many contributions to advance the field. His well balanced views were respected by colleagues from around the world. RIP

18

14

91

Anas Younes, M.D.

@DrAnasYounes

5 years

It is official, Italian patients are the reason I am not losing weight

3

2

92

Anas Younes, M.D.

@DrAnasYounes

10 months

Pleased to share that AstraZeneca announced the proposed acquisition of Gracell Biotechnologies, a biopharmaceutical company focused on developing chimeric antigen receptor T-cell (CAR-T) therapies using their rapid manufacturing technology. The acquisition is an opportunity

3

8

92

Anas Younes, M.D.

@DrAnasYounes

3 years

The joy of daily walking 55 blocks from the office to home

8

2

89

Anas Younes, M.D.

@DrAnasYounes

5 years

Recharging my batteries to get ready for 2020

4

0

83

Anas Younes, M.D.

@DrAnasYounes

5 years

Had a wonderful evening with friends and colleagues at the ⁦ @lymphoma ⁩ Research Foundation annual gala. Thanks to the LRF for honoring me tonight, and for their amazing work supporting lymphoma research

10

7

87

Anas Younes, M.D.

@DrAnasYounes

6 years

In clinic: a patient with extensive Hodgkin lymphoma, stage 4 with multiple bulky nodes, and bone involvement (Left image). In CR after standard chemotherapy (right image). Hodgkin lymphoma remains among the most curable lymphomas, even though it is extensive disease!

6

15

83

Anas Younes, M.D.

@DrAnasYounes

5 years

In Clinic: A note from a patient’s family made my day!

3

4

82

Anas Younes, M.D.

@DrAnasYounes

4 years

Very encouraging early results with ALLO-501 "off the shelf" CAR T. A bit complicated process with knocking out 2 genes and introducing a CD19 and CD20 binding proteins. No GVHD, 50% infection. 50% CR rate in 8 adequately treated pts. To be watched as more pts are treated

2

37

80

Anas Younes, M.D.

@DrAnasYounes

6 years

Very sad to hear about the passing of a good friend and colleague Prof Bertrand Coiffier. A huge loss to the lymphoma field. His contributions go beyond RCHOP, and his work touched the lives of too many patients from around the world. He will be tremendously missed. RIP!

Thierry Philip

@ThierryPhilip

6 years

Mort du professeur Bertrand Coiffier :un très grand de l hématologie RESPECT

2

9

15

3

42

80

Anas Younes, M.D.

@DrAnasYounes

2 years

Brain storming with the heme team!

4

3

81

Anas Younes, M.D.

@DrAnasYounes

4 years

Ran into a past patient in a coffee shop, and was very happy to see how well she is, living healthy and normal life. The smile on her face when she saw me made my day! #GoodFriday

2

0

80

Anas Younes, M.D.

@DrAnasYounes

5 years

A beautiful day in NYC

6

1

78

Anas Younes, M.D.

@DrAnasYounes

5 years

Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. - PubMed - NCBI

1

33

79

Anas Younes, M.D.

@DrAnasYounes

7 years

Lots of admiration and respect for patients who participate in early clinical trials. Her story inspired and energized the CAR T cell therapy field, and now we have 2 of them approved by the FDA, and more to come

Stand Up To Cancer

@SU2C

7 years

Emily Whitehead, the first child to receive CAR-T treatment for leukemia, is named one of the "10 people who mattered this year" by @nature , the top journal of multidisciplinary science, marking FDA approval of the treatment, supported by #SU2C research.

6

77

200

2

37

77

Anas Younes, M.D.

@DrAnasYounes

5 years

In Clinic: A patient with transformed follicular lymphoma, still in complete remission 4 years later. Despite the extensive disease, treatment can be very effective

1

12

77

Anas Younes, M.D.

@DrAnasYounes

2 years

Reading through the many #ASH22 AML abstracts: despite the excellent scientific advances reported in recent years, this has not translated into new transformative medicines, and the OS remains poor. AML remains a major area with unmet medical needs. More innovation is needed!

Anas Younes, M.D.

@DrAnasYounes

2 years

Raining all weekend, which is perfect to stay home and catch up on #ASH22 abstracts. I still like to print them out and read! Which abstracts are exciting to you this year?

1

3

28

3

10

76

Anas Younes, M.D.

@DrAnasYounes

5 years

I am delighted to share that LRF will be honoring me at this year's Gala with the Distinguished Leadership Award. I would like to invite you to participate by supporting the Lymphoma Research Foundation @LymphomaResearch using this link.

9

8

77

Anas Younes, M.D.

@DrAnasYounes

3 years

I am delighted to announce that Dr. Daniel (“Dan”) Auclair @AuclairDan has been appointed Executive Director, Head of Translational Medicine joining our Haematology R&D group on Monday, February 7, 2022. In his new role, Dan will provide leadership in…

Anas Younes on LinkedIn: I am delighted to announce that Dr. Daniel (“Dan”) Auclair @AuclairDan...

I am delighted to announce that Dr. Daniel (“Dan”) Auclair @AuclairDan has been appointed Executive Director, Head of Translational Medicine joining our… | 25 comments on LinkedIn

www.linkedin.com

15

7

77

Anas Younes, M.D.

@DrAnasYounes

3 years

With Tak Mak, catching up on the science and life

4

1

72

Anas Younes, M.D.

@DrAnasYounes

6 years

Glad to see that our paper ranked In the top 5% of all research outputs scored by Altmetric within a few days of its publication. Clearly there is a high interest in developing new frontline regimens for patients with DLBCL

Journal of Clinical Oncology

@JCO_ASCO

6 years

Ibrutinib plus R-CHOP in untreated non-GCB diffuse large B-cell lymphoma - the PHOENIX study, reported by @DrAnasYounes @sloan_kettering & colleagues #lymsm

0

5

12

2

8

69

Anas Younes, M.D.

@DrAnasYounes

6 years

Less is better in DLBCL: Two studies showed 4 is as good as 6 cycles of RCHOP in early stage non bulky good risk patients, and 6 is as good as 8 cycles of RCHOP in advanced stage DLBCL #ASH18

3

31

67

Anas Younes, M.D.

@DrAnasYounes

3 years

Recharging my batteries

5

0

69

Anas Younes, M.D.

@DrAnasYounes

3 years

Reviewing abstracts from #ASH21 .. Many excellent studies focusing on CART, and T cell engages, which will continue to change the standard of care in blood cancers… The next wave of innovation in blood cancers will be more novel ADCs, epigenetics modifiers, and degraders

0

2

66

Anas Younes, M.D.

@DrAnasYounes

5 years

also Berlin philharmonic @BerlinPhil is offering free streaming of their entire digital library for a month. An incredible treat while you shelter in. Here is the link #StayHomeSaveLives

1

24

66

Anas Younes, M.D.

@DrAnasYounes

6 years

It is the first study in newly diagnosed DLBCL to show a survival benefit over standard RCHOp, but the benefit is limited to those younger than 65 years of age. Older patients had increased toxicity, dose reductions/interruption that impacted the efficacy. #ASH18

Graham Collins

@graham74GC

6 years

Younes et al - marked difference in EFS and OS of RCHOP + ibrutinib vs RCHOP + placebo in front line DLBCL - Phoenix study. Over 65s had unexpected toxicity signal. Emphasises caution needed introducing new drugs in combo. #ASH2018 #lymsm

4

28

61

3

25

65

Anas Younes, M.D.

@DrAnasYounes

6 years

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincris...

PURPOSEIbrutinib has shown activity in non–germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide,...

ascopubs.org

3

27

66

Anas Younes, M.D.

@DrAnasYounes

6 years

Just finished a tour of our new ⁦ @sloan_kettering ⁩ outpatient clinical building which will open in November. Amazing state of the art, patient-friendly facility. Clinic visits, diagnostic imaging, biopsies, and treatment area, all under one roof

5

11

62

Anas Younes, M.D.

@DrAnasYounes

4 years

After 2 months of lockdown, a historic lunch with my wife in an outdoor cafe in NYC. Social distancing is enforced, and people wear their masks between bites...I think this is going to be the future of dining out, which is better than the alternatives. #IAmHappy #PerfectWeather

4

2

66

Anas Younes, M.D.

@DrAnasYounes

7 years

Love to give good news to patients, especially around the holidays... Lymphoma is a responsive disease to therapy even when it is bulky and spread out. The difference between these two PET scans is only 2 cycles of therapy.

4

10

61

Anas Younes, M.D.

@DrAnasYounes

7 years

In clinic: happy to see 2 of my young patients being pregnant after they were treated for Hodgkin and non-Hodgkin lymphoma and are cured of their disease. Patients can and should live a normal life after cancer

4

9

62

Anas Younes, M.D.

@DrAnasYounes

10 months

Congrats to ⁦Omar @AbdelWahablab ⁩ @msk for the #ASH23 Dameshek Award. Very well deserved !

2

7

64

Anas Younes, M.D.

@DrAnasYounes

11 months

If you are getting dizzy reading all #ASH23 abstracts on T cell engagers across all major indications (lymphoma, Mm,,AML), with different schedules (weekly, Q2wks, Q3wks, Q4wks), route of administration(IV, SQ, or both), different length of therapy (1 year, 2 years, or until

1

4

64

Anas Younes, M.D.

@DrAnasYounes

5 years

in Clinic: A patient with multiple enlarged lymph nodes, SUV max 22 and 29. Biopsy from 2 different nodes showed FL grade 1-2. Would you treat with BR or RCHOP (right fig after treatment)

55

14

63

Anas Younes, M.D.

@DrAnasYounes

3 years

Really great catching up with ⁦ @rosslevinemd ⁩ after his inspiring keynote lecture to our oncology R&D group. Clonal hematopoiesis science is opening new possibilities to intercept cancer early on to make an impact on patients’ lives

0

1

63

Anas Younes, M.D.

@DrAnasYounes

2 years

With Michael Kharas ⁦ @KharasLab ⁩ celebrating our recently published collaborative paper in ⁦ @NatureComms ,⁩ and plotting our new collaboration

1

62

Anas Younes, M.D.

@DrAnasYounes

6 years

The emptiness at the end of #ASH18 . Back in NYC tomorrow with a few new practice changing data that will hopefully improve the lives of our patients

1

9

62

Anas Younes, M.D.

@DrAnasYounes

3 years

An extraordinary day celebrating Jose Baselga’s legacy at ⁦⁦ @AstraZenecaUS ⁩

1

3

62

Anas Younes, M.D.

@DrAnasYounes

5 years

You can download a powerpoint slide of the single agent activity landscape in the most common B cell lymphomas => New drugs for new targets in lymphoma - Younes - 2019 - Hematological Oncology -

1

24

61

Anas Younes, M.D.

@DrAnasYounes

4 years

Hot off the press

4

42

60

Anas Younes, M.D.

@DrAnasYounes

5 years

Stopped in my office before clinic. Have not been there in 2 weeks..clinic will be mostly telemedicine and phone calls..I already miss the human interaction with patients. Nothing compares to putting your hand on a patient’s shoulder and say “don’t worry” #COVID19

5

0

58

Anas Younes, M.D.

@DrAnasYounes

11 months

More #ASH23 abstracts to be read, and more coffee to be sipped. I still like to print out abstracts that I am interested in reading. I think I am one of a few who misses having the old abstract book!

3

2

60

Anas Younes, M.D.

@DrAnasYounes

5 years

66 YOM with generalized adenopathy with high SUV (max 22). Biopsies from 2 different lymph nodes with high SUV showed Follicular Lymphoma grade 1-2. I chose to treat with RCHOP suspecting transformation, instead of BR. Images before and after are shown.

4

57

Anas Younes, M.D.

@DrAnasYounes

4 years

On the water for the ultimate #SocialDistanacing

3

0

56

Anas Younes, M.D.

@DrAnasYounes

2 years

Wrote chapters in the latest editions of both textbooks (and got my free copies!)…I still see value for having standard text books as they contain solid core information, even though they can’t stay completely up to date..

5

2

54

Anas Younes, M.D.

@DrAnasYounes

6 years

CAR T cells, Antibody drug conjugates, Lenalidomide/Rituxan, and Anti CD47/Rituxan are the highlights of #ASCO18 fo lymphoma. Good news for immune therapy and for patients. But we should not get distracted and continue our efforts to identify new targets through basic science

3

25

53

Anas Younes, M.D.

@DrAnasYounes

5 years

Coffee with our special visiting Spanish lymphoma expert Dr Sabella Bobillo. Going back home to Barcelona after spending a year with us at ⁦ @sloan_kettering ⁩

1

2

54

Anas Younes, M.D.

@DrAnasYounes

2 years

Super happy to team up with ⁦ @ninashah33 ⁩

0

2

53

Anas Younes, M.D.

@DrAnasYounes

4 years

Cytokine release syndrome in severe COVID-19

2

24

53

Anas Younes, M.D.

@DrAnasYounes

5 years

Just got my copy, did you get yours?

9

6

54

Anas Younes, M.D.

@DrAnasYounes

3 years

Had a great time with our talented hematology R&D group in Cambridge. Their energy, passion, and knowledge are inspiring.

2

0

54

Anas Younes, M.D.

@DrAnasYounes

4 years

The new norm for a coffee break..A brief opportunity to take off the mask... #WearAMask

3

1

55

Anas Younes, M.D.

@DrAnasYounes

6 years

In Clinic: A patient with diffuse large B cell lymphoma, one year after treatment with immunochemotherapy. We can cure approximately 60% to 65% of all patients, but there is room for improvement. Working on developing better therapy

4

8

54

Anas Younes, M.D.

@DrAnasYounes

3 years

One of us is 1 year older (and wiser)

4

0

54

Anas Younes, M.D.

@DrAnasYounes

5 years

Beautiful moonrise in Lugano

2

52

Anas Younes, M.D.

@DrAnasYounes

6 years

A beautiful morning in Chicago. Off to my first morning meeting to discuss immunotherapy biomarkers

3

8

51

Anas Younes, M.D.

@DrAnasYounes

5 years

My first baguettes..I learned something new during the lockdown..

6

0

53

Anas Younes, M.D.

@DrAnasYounes

1 year

Really nice to see my good old friend and colleague Dr Jason Westin ⁦ @Lymphoma_Doc ⁩ in his office at ⁦ @MDAndersonNews ⁩ (which was my old office!)

2

53

Anas Younes, M.D.

@DrAnasYounes

6 years

Our review paper is just published in ⁦ @NatRevClinOncol ⁩ : Emerging epigenetic-modulating therapies in lymphoma

3

23

51

Anas Younes, M.D.

@DrAnasYounes

5 years

At the annual Central Park picnic celebrating the wonderful work of my ⁦clinic, office, and lab teams ⁦ @sloan_kettering ⁩

1

4

50

Anas Younes, M.D.

@DrAnasYounes

6 years

Morning hospital rounds at the lymphoma center of the 1st Affiliated Hospital of Zhengzhou University, the largest hospital in China with 10,000 beds. Lymphoma census today was 170. Amazing clinical staff who work tirelessly to take care of a large number of patients

5

6

51

Anas Younes, M.D.

@DrAnasYounes

2 years

Playing tourist with my wife

1

0

50

Anas Younes, M.D.

@DrAnasYounes

6 years

Ibrutinib plus rituximab vs FCR in Untreated Younger Patients with CLL : Amazing results favoring Ibrutinib #ASH18

3

18

48

Anas Younes, M.D.

@DrAnasYounes

6 years

Back on hospital service = slow response to emails (and = more coffee). Every patient has a story, and I love listening to them, one story at a time! We treat patients, not just the disease!

2

6

49

Anas Younes, M.D.

@DrAnasYounes

5 years

Locked-in at home, running and participating in meetings by phone and webex... Had my first virtual lab meeting today..Who would have thought I would be running a lab meeting in my pajamas...This used to happen only in my nightmares. #COVID19 #WFH

2

3

48

Anas Younes, M.D.

@DrAnasYounes

9 years

Spectacular sunset in NYC

0

17

48

Anas Younes, M.D.

@DrAnasYounes

4 years

The semi official welcoming ceremony for ⁦ @gilles_salles ⁩ ( with Dogan and Yahalom)

0

2

47

Anas Younes, M.D.

@DrAnasYounes

7 years

On Hospital Rounds-discussing experimental therapy: Patient: I do not want to be a guinea pig Me: You are not. The goal of experimental therapy is not to experiment on you, but to try to help you through new promising treatments. Need to improve public trust in clinical trials

0

21

45

Anas Younes, M.D.

@DrAnasYounes

5 years

In Clinic: working with the most wonderful and dedicated clinical staff in the world to take care of our patients during this unusual time. Most visits are done by telemedicine to reduce risks. Life saving therapy continues.. #StayHomeAndStaySafe

3

1

50

Anas Younes, M.D.

@DrAnasYounes

3 years

It has been a year since I joined AstraZeneca to build and lead the new Hematology R&D team. And this past year was like no other!. Making a major career change and building a new team in the middle of a global pandemic was not without risks. We had t…

Anas Younes on LinkedIn: It has been a year since I joined AstraZeneca to build and lead the new… |...

It has been a year since I joined AstraZeneca to build and lead the new Hematology R&D team. And this past year was like no other!. Making a major career… | 43 comments on LinkedIn

www.linkedin.com

4

1

48

Anas Younes, M.D.

@DrAnasYounes

5 years

Delighted to see that patients are increasingly coming to @sloan_kettering for diagnosis and initial therapy of lymphoma

6

46

Anas Younes, M.D.

@DrAnasYounes

2 years

Proud of our Clinical Development team, managing 30 clinical trials in hematology, and looking forward to do more. They all have the same passion, to bring new and impactful medicines to patients with all types of blood cancers

2

0

45

Anas Younes, M.D.

@DrAnasYounes

3 years

As the day gets shorter, my walk back home becomes more fun #10K -Steps

2

0

46

Anas Younes, M.D.

@DrAnasYounes

6 years

Dear @CastleConnolly : Thank you for the honor and for the recognition as a top doctor in Houston for 2019, even though I have moved to New York to work at @sloan_kettering 5 years ago

2

3

46

Anas Younes, M.D.

@DrAnasYounes

2 years

Reviewing #ASH22 abstracts while a full moon rises over the Mississippi

1

0

47

Anas Younes, M.D.

@DrAnasYounes

5 years

Getting ready for Nadal vs Medvedev #USOpen

0

1

47

Anas Younes, M.D.

@DrAnasYounes

4 years

A beautiful day

1

48

Anas Younes, M.D.

@DrAnasYounes

4 years

COVID19 is the mother of invention...

0

15

47

Anas Younes, M.D.

@DrAnasYounes

5 years

Really? Stem Cell Food?! Not sure what that means? Any ideas!

22

11

46

Anas Younes, M.D.

@DrAnasYounes

3 years

Beautiful fall day in ⁦ @CentralParkNYC ⁩

0

2

47

Anas Younes, M.D.

@DrAnasYounes

4 years

A quick review of #ASH20 presentations shows how T cell engagers and CAR T cell therapy are quickly changing the treatment landscape of blood cancers. More scientific discoveries are quickly translated into innovative therapies. Will chemotherapy become obsolete? I wonder& I hope

3

5

46

Anas Younes, M.D.

@DrAnasYounes

4 years

Good luck to all ⁦ @sloan_kettering Heme/Onc graduating fellows. Zoom may not be the ideal way to celebrate, but it was great to see the future leaders in their home settings with their loved ones. An added bonus of fellowship training is many new life-long friendships

0

2

45

Anas Younes, M.D.

@DrAnasYounes

4 years

There is something therapeutic about walking on an empty beach

3

0

44

Anas Younes, M.D.

@DrAnasYounes

3 years

Was watching thanksgiving parade with my wife in a small town outside New York, when out of no where an old patient of mine popped out to say hello, and introduced his wife and kids to us #MadeMyDay

0

43

Anas Younes, M.D.

@DrAnasYounes

5 years

My favorite combination for a long weekend: coffee, books, and nature

1

5

44

Anas Younes, M.D.

@DrAnasYounes

4 years

We are rapidly building a world-class hematology R&D team. Our goal is very clear, we want to improve the cure rate for patients with blood cancers #WorldCancerDay

0

4

43

Anas Younes, M.D.

@DrAnasYounes

2 years

Great hosting ⁦my good friend and former ⁦ @MSKCancerCenter ⁩ colleague @AbdelWahablab ⁩ with our GPL Gülu Gorgun. Scientific exchange of ideas and collaborations between academia and industry are critical to accelerate drug development for patients with cancer.

1

0

44